

Resource Summary Report

Generated by [RRID](#) on Sep 19, 2026

[Inxight](#)

RRID:SCR_016490

Type: Tool

Proper Citation

Inxight (RRID:SCR_016490)

Resource Information

URL: <https://drugs.ncats.io/>

Proper Citation: Inxight (RRID:SCR_016490)

Description: Portal of NCATS (the National Center for Advancing Translational Sciences) for drug development information including:US approved drugs, marketed drugs, investigational drugs. Provides manually curated data supplied by the FDA and private companies. Provides drugs marketing and regulatory status, drug ingredient definitions, biological activity and clinical use.

Resource Type: data or information resource, database, organization portal, portal

Keywords: drug, development, information, approved, marketed, investigational, data, supply, FDA, company, regulatory, status, ingredient, definition, biological, activity, clinical, use

Funding: NIH

Availability: Free, Freely available

Resource Name: Inxight

Resource ID: SCR_016490

License: General Public

Record Creation Time: 20220129T080330+0000

Record Last Update: 20260912T200104+0000

Ratings and Alerts

No rating or validation information has been found for Inxight.

No alerts have been found for Inxight.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 16 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Mahdi-Esferizi R, et al. (2024) Single-cell transcriptional signature-based drug repurposing and in vitro evaluation in colorectal cancer. BMC cancer, 24(1), 371.

Palazzotti D, et al. (2024) Small Molecule Drugs Targeting Viral Polymerases. Pharmaceuticals (Basel, Switzerland), 17(5).

Mou Z, et al. (2024) Quantitative Structure-Activity Relationship Models to Predict Cardiac Adverse Effects. Chemical research in toxicology, 37(12), 1924.

Knorr DA, et al. (2024) Fc??RIIB Is an Immune Checkpoint Limiting the Activity of Treg-Targeting Antibodies in the Tumor Microenvironment. Cancer immunology research, 12(3), 322.

Lavrador M, et al. (2023) A Universal Pharmacological-Based List of Drugs with Anticholinergic Activity. Pharmaceutics, 15(1).

Rigden DJ, et al. (2022) The 2022 Nucleic Acids Research database issue and the online molecular biology database collection. Nucleic acids research, 50(D1), D1.

Ragon B, et al. (2022) Using informatics to advance translational science: Environmental scan of adaptive capacity and preparedness of Clinical and Translational Science Award Program hubs. Journal of clinical and translational science, 6(1), e76.

Rao SJA, et al. (2022) Structure-based screening of natural product libraries in search of potential antiviral drug-leads as first-line treatment to COVID-19 infection. Microbial pathogenesis, 165, 105497.

Savva K, et al. (2022) Network-based stage-specific drug repurposing for Alzheimer's disease. Computational and structural biotechnology journal, 20, 1427.

Sierra B, et al. (2021) Multi-Tissue Transcriptomic-Informed In Silico Investigation of Drugs for the Treatment of Dengue Fever Disease. Viruses, 13(8).

Vitale DL, et al. (2021) Targeting the Tumor Extracellular Matrix by the Natural Molecule 4-Methylumbelliferone: A Complementary and Alternative Cancer Therapeutic Strategy. Frontiers in oncology, 11, 710061.

Negraes PD, et al. (2021) Altered network and rescue of human neurons derived from individuals with early-onset genetic epilepsy. Molecular psychiatry, 26(11), 7047.

Austin CP, et al. (2021) Opportunities and challenges in translational science. Clinical and translational science, 14(5), 1629.

Kenda M, et al. (2020) Computational Study of Drugs Targeting Nuclear Receptors. Molecules (Basel, Switzerland), 25(7).

Bandara S, et al. (2020) Analysis of the health product pipeline for poverty-related and neglected diseases using the Portfolio-to-Impact (P2I) modeling tool. F1000Research, 9, 416.

Coussens NP, et al. (2018) Better living through chemistry: Addressing emerging antibiotic resistance. Experimental biology and medicine (Maywood, N.J.), 243(6), 538.